Mirum Pharmaceuticals shares are higher Friday, April 17, 2026, with the tape reflecting incremental bullish positioning rather than a single major headline. The latest identifiable fundamental spark is a recent bullish analyst stance: an April 10, 2026 update that maintained a Buy rating with a $140 price target, reinforcing the market’s confidence in Mirum’s rare-disease commercial trajectory and pipeline optionality.

Mirum’s short interest remains elevated, which can make day-to-day moves more volatile when demand picks up. As of March 31, 2026, short interest was about 8.05 million shares, roughly 15.6% of the public float, a setup that can accelerate upside when the stock trends higher and short sellers reduce exposure.

The most recent company update in mid-April is a routine inducement-grant disclosure (equity awards to new employees) dated April 10, 2026. That type of item is generally not a fundamental revaluation catalyst by itself, suggesting today’s advance is more consistent with sentiment/positioning and follow-through from prior positive framing than with a new product, FDA, or earnings surprise.

Near-term attention stays on execution against 2026 operating goals and upcoming clinical milestones, including late-stage readouts tied to the company’s expansion beyond LIVMARLI. With Mirum also integrating its Bluejay Therapeutics acquisition and developing brelovitug (Phase 3 top-line results expected in the second half of 2026), investors will be looking for clear progress updates that can sustain the stock’s upward trend.